MedTrace Logo

Optimizing Drug Doses in Critically Ill

NCT02437838 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2017-06-20

No results posted yet for this study

Summary

The primary objectives of this study are to examine whether augmented renal clearance (ARC) compromises renally eliminated drug therapeutic serum concentrations in patients with traumatic brain injury (TBI) and to estimate the optimal dose needed to achieve therapeutic serum concentrations of the probe medication levetiracetam in patients with TBI.

Conditions

Interventions

OTHER

No Intervention

No Intervention

Sponsors & Collaborators

  • University of Kentucky

    collaborator OTHER

  • University of North Carolina, Chapel Hill

    lead OTHER

Principal Investigators

  • Kathryn Morbitzer, PharmD · University of North Carolina, Chapel Hill

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02437838 on ClinicalTrials.gov